» Articles » PMID: 16274775

Diabetes Mellitus is a Strong, Independent Risk for Atrial Fibrillation and Flutter in Addition to Other Cardiovascular Disease

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2005 Nov 9
PMID 16274775
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Diabetes mellitus (DM) is a major risk factor for atherosclerosis. There is a controversy in literature about correlation between DM and atrial fibrillation. The goal of this study was to evaluate DM as a risk factor for atrial fibrillation or flutter using a very large database.

Method: Patient treatment files (PTF) containing discharge diagnoses were utilized using ICD-9 codes of inpatient treatment from Veterans Health Administration Hospitals (VAH). Patients with type II DM (ICD-9 code 250.0) (293,124) discharged from the VAH between 1990 and 2000. Non-matched controls without DM but with hypertension (552,624) were selected from the same PTF. By using multi-variate logistic regressions, the occurrence of atrial fibrillation, atrial flutter, CHF, CAD and LVH was compared.

Results: Atrial fibrillations occurred in 43,674 (14.9%) DM patients vs. 57,077 (10.3%) in the control group (p<0.0001). Atrial flutter occurred in 11,852 (4%) of DM patients vs. 13,554 (2.5%) of the control group (p<0.0001). Using multi-variant analysis, DM remained independently associated with atrial fibrillation with an OR of 2.13, (95% CI: 2.10 to 2.16; p<0.0001) and flutter (OR 2.20, CI: 2.15 to 2.26; p<0.0001). Furthermore, CHF (OR 3.12, CI: 3.09 to 3.16; p<0.0001), LVH (OR 1.85, CI: 1.77 to 1.92; p<0.0001) and CAD (OR 2.39, CI: 2.34 to 2.44; p<0.0001) were also independently associated with DM.

Conclusion: This is the first large-scale study finding DM as a strong, independent risk for the occurrence of atrial fibrillation and flutter and other cardiovascular disease.

Citing Articles

Integrated Management of Persistent Atrial Fibrillation.

Yue X, Zhou L, Zhao C Biomedicines. 2025; 13(1).

PMID: 39857675 PMC: 11760448. DOI: 10.3390/biomedicines13010091.


Proteinuria and the risk of Incident atrial fibrillation according to glycemic stages: a nationwide population-based cohort study.

Yeo M, Lee S, Choi E, Choi J, Lee K, Kwon S Cardiovasc Diabetol. 2025; 24(1):41.

PMID: 39856720 PMC: 11762047. DOI: 10.1186/s12933-025-02590-2.


Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation.

Aydemir S, Aydin S, Aksakal E, Altinkaya O, Ozmen M, Birdal O BMC Cardiovasc Disord. 2024; 24(1):760.

PMID: 39736518 PMC: 11686956. DOI: 10.1186/s12872-024-04454-1.


Unsupervised clustering identified clinically relevant metabolic syndrome endotypes in UK and Taiwan Biobanks.

Lim A, Lim E, Chen P, Fann C iScience. 2024; 27(7):109815.

PMID: 39040048 PMC: 11260869. DOI: 10.1016/j.isci.2024.109815.


Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications.

Bode D, Pronto J, Schiattarella G, Voigt N Nat Rev Cardiol. 2024; 21(10):682-700.

PMID: 38816507 DOI: 10.1038/s41569-024-01038-6.